Advertisement

Tumor Biology

, Volume 36, Issue 12, pp 9599–9609 | Cite as

Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer

  • Junli Ma
  • Yan Zhang
  • Hong Shen
  • Linda Kapesa
  • Wenqiang Liu
  • Mengsi Zeng
  • Shan Zeng
Research Article

Abstract

Mismatch repair (MMR) gene is closely related to the pathogenesis of colon cancer. This study aimed to evaluate the association between MMR status and efficacy of irinotecan-based chemotherapy. As a target of 5-FU, thymidylate synthase (TS) expression level might be influenced by irinotecan. Understanding whether this influence of TS is related with MMR status is helpful to the further exploration of the mechanism of irinotecan sensitivity in metastatic colon cancer with different MMR status. One hundred eighty-four patients with metastatic colon cancer receiving irinotecan-based chemotherapy for the first-line treatment were included. Correlations between MMR and clinicopathological characteristics and prognosis were determined. Two pairs of colon cancer cell lines (HCT-116-hMLH1Vector (deficient MMR, dMMR) versus HCT-116-hMLH1+ (proficient MMR, pMMR); SW480-shRNA-hMLH1 (dMMR) versus SW480-shRNA-Control (pMMR)) were established by regulating MMR status. Sensitivity of these cell lines to irinotecan was determined by MTT assay. Regulation of TS by irinotecan was evaluated by western blotting and quantitative real-time PCR assay. dMMR accounted for 18.5 % and was related with proximal colon cancer (p = 0.005), poorly differentiated tumors (p = 0.018) and favorable efficacy with a higher disease control rate (DCR), a longer progression-free survival (PFS) and a trend of longer overall survival (OS). dMMR colon cancer cells were more sensitive to irinotecan. TS expression level was reduced more in dMMR cells after irinotecan treatment (p < 0.05). Our study favors an increased sensitivity of irinotecan in colon cancer with dMMR status. MMR status may be a predictive biomarker of response to irinotecan-based chemotherapy in metastatic colon cancer.

Keywords

Colon cancer Mismatch repair gene Irinotecan 5-Fluorouracil Thymidylate synthase 

Notes

Acknowledgments

This study was supported by the grants from the National Nature Science Foundation of China (nos. 30770971, 81172470, 81070362, and 81372629).

Compliance with ethical standards

The manuscript has been performed with the approval of the ethics of Xiangya Hospital, Central South University. Informed consent was obtained from all the patients before enrollment in the study. This study was prospectively performed and approved by the institutional Ethics Committees of our hospital and conducted in accordance with the ethical guidelines of the Declaration of Helsinki.

Conflict of interest

The authors declare that they have no competing interests.

Supplementary material

13277_2015_3723_Fig6_ESM.gif (24 kb)
Supplementary Fig. S1

Two hundred nineteen patients with metastatic colon cancer receiving irinotecan-based chemotherapy as the first-line treatment were randomly collected at first. Exclusion criteria: combined chemotherapy with targeted agents (n=17); insufficiency of tumor tissues (n=11); prior cytotoxic or radiation therapy (n=5); severe cardiopulmonary disease or other systematic diseases precluding standard chemotherapy (n=2). At last 184 subjects were finally included (170 cases for FOLFIRI, 1 for XELIRI and 13 for irinotecan only) (GIF 24 kb)

13277_2015_3723_MOESM1_ESM.tif (1.2 mb)
High Resolution Image (TIFF 1185 kb)
13277_2015_3723_Fig7_ESM.gif (30 kb)
Supplementary Fig. S2

MMR status of the two colon cells HCT-116 and SW480 were checked by Western blot and qRT-PCR before the cytological experiment. hMLH1 was expressed normally in SW480 cells while absent in HCT-116 cells (p<0.001) (GIF 30 kb)

13277_2015_3723_MOESM2_ESM.tif (787 kb)
High Resolution Image (TIFF 787 kb)
13277_2015_3723_MOESM3_ESM.docx (14 kb)
Supplementary Table S1 (DOCX 13 kb)
13277_2015_3723_MOESM4_ESM.docx (14 kb)
Supplementary Table S2 (DOCX 13 kb)

References

  1. 1.
    Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64:104–17.CrossRefPubMedGoogle Scholar
  2. 2.
    Gibson J, Lacy J, Matloff E, Robert M. Microsatellite instability testing in colorectal carcinoma: a practical guide. Clin Gastroenterol Hepatol. 2014;12:171–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Buecher B, Cacheux W, Rouleau E, Dieumegard B, Mitry E, et al. Role of microsatellite instability in the management of colorectal cancers. Dig Liver Dis. 2013;45:441–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383:1490–502.CrossRefPubMedGoogle Scholar
  5. 5.
    Pino MS, Chung DC. Microsatellite instability in the management of colorectal cancer. Expert Rev Gastroenterol Hepatol. 2011;5:385–99.CrossRefPubMedGoogle Scholar
  6. 6.
    Lin CC, Lai YL, Lin TC, Chen WS, Jiang JK, et al. Clinicopathologic features and prognostic analysis of MSI-high colon cancer. Int J Color Dis. 2012;27:277–86.CrossRefGoogle Scholar
  7. 7.
    Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res. 2001;61:5193–201.PubMedGoogle Scholar
  8. 8.
    Duldulao MP, Lee W, Le M, Chen Z, Li W, et al. Gene expression variations in microsatellite stable and unstable colon cancer cells. J Surg Res. 2012;174:1–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Devaud N, Gallinger S. Chemotherapy of MMR-deficient colorectal cancer. Familial Cancer. 2013;12:301–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011;103:863–75.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Juo YY, Johnston FM, Zhang DY, Juo HH, Wang H, et al. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol. 2014;25:2314–27.Google Scholar
  12. 12.
    Sato K, Kitajima Y, Kohya N, Koga Y, Ohtaka K, et al. CPT-11 (SN-38) chemotherapy may be selectively applicable to biliary tract cancer with low hMLH1 expression. Anticancer Res. 2007;27:865–72.PubMedGoogle Scholar
  13. 13.
    Bendardaf R, Lamlum H, Ristamaki R, Korkeila E, Syrjanen K, et al. Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer. Tumour Biol. 2007;28:212–20.CrossRefPubMedGoogle Scholar
  14. 14.
    Vilar E, Scaltriti M, Balmana J, Saura C, Guzman M, et al. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer. 2008;99:1607–12.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol. 2009;27:1814–21.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Bhonde MR, Hanski ML, Stehr J, Jebautzke B, Peiro-Jordan R, et al. Mismatch repair system decreases cell survival by stabilizing the tetraploid G1 arrest in response to SN-38. Int J Cancer. 2010;126:2813–25.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Torigoe S, Ogata Y, Matono K, Shirouzu K. Molecular mechanisms of sequence-dependent antitumor effects of SN-38 and 5-fluorouracil combination therapy against colon cancer cells. Anticancer Res. 2009;29:2083–9.PubMedGoogle Scholar
  18. 18.
    Fukushima M, Sakamoto K, Ohshimo H, Nakagawa F, Taguchi T. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase. Oncol Rep. 2010;24:835–42.PubMedGoogle Scholar
  19. 19.
    Zeng S, Tao Y, Huang J, Zhang S, Shen L, et al. WD40 repeat-containing 62 overexpression as a novel indicator of poor prognosis for human gastric cancer. Eur J Cancer. 2013;49:3752–62.CrossRefPubMedGoogle Scholar
  20. 20.
    Shen LF, Chen J, Zeng S, Zhou RR, Zhu H, et al. The superparamagnetic nanoparticles carrying the E1A gene enhance the radiosensitivity of human cervical carcinoma in nude mice. Mol Cancer Ther. 2010;9:2123–30.CrossRefPubMedGoogle Scholar
  21. 21.
    Yoon YS, Yu CS, Kim TW, Kim JH, Jang SJ, et al. Mismatch repair status in sporadic colorectal cancer: immunohistochemistry and microsatellite instability analyses. J Gastroenterol Hepatol. 2011;26:1733–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138:2073–87.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Fallik D, Borrini F, Boige V, Viguier J, Jacob S, et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 2003;63:5738–44.PubMedGoogle Scholar
  24. 24.
    Kim JC, Roh SA, Cho DH, Kim TW, Yoon SN, et al. Chemoresponsiveness associated with canonical molecular changes in colorectal adenocarcinomas. Anticancer Res. 2009;29:3115–23.PubMedGoogle Scholar
  25. 25.
    Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol. 2008;26:2690–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100:266–73.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Kim JE, Hong YS, Ryu MH, Lee JL, Chang HM, et al. Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer. Cancer Sci. 2011;102:1706–11.CrossRefPubMedGoogle Scholar
  28. 28.
    Kim TW, Innocenti F. Insights, challenges, and future directions in irinogenetics. Ther Drug Monit. 2007;29:265–70.CrossRefPubMedGoogle Scholar
  29. 29.
    Kim JH, Shin SH, Kwon HJ, Cho NY, Kang GH. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch. 2009;455:485–94.CrossRefPubMedGoogle Scholar
  30. 30.
    Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013;105:1151–6.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Samadder NJ, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, et al. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women. Gastroenterology. 2013;145:348–56.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Kim JH, Kang GH. Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. World J Gastroenterol. 2014;20:4230–43.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Fedier A, Schwarz VA, Walt H, Carpini RD, Haller U, et al. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int J Cancer. 2001;93:571–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Jacob S, Aguado M, Fallik D, Praz F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res. 2001;61:6555–62.PubMedGoogle Scholar
  35. 35.
    Magrini R, Bhonde MR, Hanski ML, Notter M, Scherubl H, et al. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer. 2002;101:23–31.CrossRefPubMedGoogle Scholar
  36. 36.
    Elliott B, Jasin M. Repair of double-strand breaks by homologous recombination in mismatch repair-defective mammalian cells. Mol Cell Biol. 2001;21:2671–82.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Tahara M, Inoue T, Sato F, Miyakura Y, Horie H, et al. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks. Mol Cancer Ther. 2014;13:1170–80.CrossRefPubMedGoogle Scholar
  38. 38.
    Inoue Y, Tanaka K, Hiro J, Yoshiyama S, Toiyama Y, et al. in vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer. Int J Oncol. 2006;28:479–86.PubMedGoogle Scholar
  39. 39.
    Guichard S, Cussac D, Hennebelle I, Bugat R, Canal P. Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer. 1997;73:729–34.CrossRefPubMedGoogle Scholar
  40. 40.
    Inoue Y, Miki C, Watanabe H, Hiro J, Toiyama Y, et al. Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line. J Gastroenterol. 2006;41:1149–57.CrossRefPubMedGoogle Scholar
  41. 41.
    Cao S, Rustum YM. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Res. 2000;60:3717–21.PubMedGoogle Scholar
  42. 42.
    Azrak RG, Cao S, Slocum HK, Toth K, Durrani FA, et al. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res. 2004;10:1121–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Ide H, Kikuchi E, Hasegawa M, Hattori S, Yasumizu Y, et al. Therapeutic enhancement of S-1 with CPT-11 through down-regulation of thymidylate synthase in bladder cancer. Cancer Med. 2013;2:488–95.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Takiuchi H, Kawabe S, Gotoh M, Katsu K. Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer. Gastrointest Cancer Res. 2007;1:171–6.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Jensen SA, Vainer B, Kruhoffer M, Sorensen JB. Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression. BMC Cancer. 2009;9:25.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Kristensen MH, Weidinger M, Bzorek M, Pedersen PL, Mejer J. Correlation between thymidylate synthase gene variants, RNA and protein levels in primary colorectal adenocarcinomas. J Int Med Res. 2010;38:484–97.CrossRefPubMedGoogle Scholar
  47. 47.
    Ohrling K, Karlberg M, Edler D, Hallstrom M, Ragnhammar P. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer. Clin Colorectal Cancer. 2013;12:128–35.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Junli Ma
    • 1
  • Yan Zhang
    • 1
  • Hong Shen
    • 2
  • Linda Kapesa
    • 1
  • Wenqiang Liu
    • 1
  • Mengsi Zeng
    • 1
  • Shan Zeng
    • 1
  1. 1.Department of Oncology, Xiangya HospitalCentral South UniversityChangshaChina
  2. 2.Institute of Medical Sciences, Xiangya HospitalCentral South UniversityChangshaChina

Personalised recommendations